uniQure (NASDAQ:QURE) Stock Crosses Below 50-Day Moving Average - What's Next?

Key Points

• uniQure's stock has traded below its 50-day moving average, with current prices at $13.66 against a moving average of $15.24.
• Wall Street analysts have mixed ratings on the stock, with two strong buy, seven buy, and two hold ratings, and an average price target of $37.45.
• Recent institutional investments include significant stakes from Jefferies Financial Group and JPMorgan Chase, highlighting increasing institutional interest, as they now own 78.83% of the company's stock.

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of $15.24 and traded as low as $13.65. uniQure shares last traded at $13.66, with a volume of 1,003,204 shares trading hands.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Wall Street Zen raised uniQure from a "sell" rating to a "hold" rating in a report on Saturday, August 2nd. Cantor Fitzgerald set a $47.00 price objective on uniQure in a report on Wednesday, July 30th. HC Wainwright reissued a "buy" rating and issued a $70.00 price objective on shares of uniQure in a report on Friday, September 5th. Mizuho raised uniQure from a "neutral" rating to an "outperform" rating and set a $30.00 price objective for the company in a report on Thursday, August 14th. Finally, Chardan Capital reissued a "buy" rating and issued a $35.00 price objective on shares of uniQure in a report on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $37.45.

uniQure Stock Down 1.2%

The firm has a market cap of $749.52 million, a price-to-earnings ratio of -3.48 and a beta of 0.14. The company has a current ratio of 9.98, a quick ratio of 9.98 and a debt-to-equity ratio of 1.53. The firm has a 50 day moving average price of $15.24 and a 200-day moving average price of $14.09.

uniQure (NASDAQ:QURE - Get Free Report) last released its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.20. The business had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative return on equity of 1,010.74% and a negative net margin of 1,387.98%. On average, equities analysts forecast that uniQure N.V. will post -3.75 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Jefferies Financial Group Inc. purchased a new stake in uniQure during the 2nd quarter worth about $29,217,000. Vestal Point Capital LP increased its position in uniQure by 58.4% during the 1st quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock worth $50,801,000 after purchasing an additional 1,767,572 shares in the last quarter. JPMorgan Chase & Co. increased its position in uniQure by 471.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company's stock worth $25,199,000 after purchasing an additional 1,491,486 shares in the last quarter. Sofinnova Investments Inc. increased its position in uniQure by 185.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company's stock worth $21,723,000 after purchasing an additional 1,012,585 shares in the last quarter. Finally, Aberdeen Group plc increased its position in uniQure by 46.8% during the 1st quarter. Aberdeen Group plc now owns 2,215,551 shares of the biotechnology company's stock worth $23,485,000 after purchasing an additional 706,216 shares in the last quarter. Institutional investors and hedge funds own 78.83% of the company's stock.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.